Pulmonology

A discussion on how thromboembolism research and care could benefit from progression in diagnostics.

Patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less had an adjusted hazard ratio for mortality of 1.71.

The approval are based on a pair of recent phase 3 trials showing the safety and efficacy of budesonide/glycopyrrolate/formoterol fumarate.

Until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care

A two-week period of downward COVID-19 cases is needed before reigniting elective procedures.

Genomics, in combination with patient demographic risks, could help better inform clinicians of persons at risk for worsened chronic pulmonary burden.

A noninferiority study showed parents were not more anxious when their discharged child was treated as-need—nor was their child at greater health risk.

There is also an association between late onset of spring and an increase in hospital admissions for asthma.

ADHD, autism spectrum disorder, seizures, and even developmental delays are asssociated with a two-fold risk of asthma in US children.

Dexamethasone should also be used for up to 10 days in patients with COVID-19 who require supplemental oxygen but are not mechanically ventilated.

Where do investigators go next with the 8000-plus COPD patient research?

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

The therapy reduces death by 35% in patients with respiratory complications.

What risks of severity do patients face with viral infection?

A look at how the rare pulmonary disease field of research has been limited.

A look at the appropriate referral and promising agents for care of the rare pulmonary disease.

Greg Cosgrove, MD, explains how the respiratory condition can be overlooked by patients and clinicians.

A new Canadian Thoracic Society guidance sets recommendations for continued or halted use of inhaled steroids, nebulizers, biologics, and more.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Asthmatic infants often suffer from other comorbidities throughout their lives.